Innoviva, Inc. (INVA) Financials

INVA Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 1.8 billion 494.9 million
Dec. 31, 2025 1.6 billion 462.3 million
Sept. 30, 2025 1.4 billion 419.2 million
June 30, 2025 1.3 billion 618.8 million

INVA Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 34.8 million ?
Dec. 31, 2025 53.4 million 16.2 million
Sept. 30, 2025 48.6 million 2.4 million
June 30, 2025 44.1 million 2.4 million

INVA Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 186.6 million
Dec. 31, 2025 241.7 million
Sept. 30, 2025 89.9 million
June 30, 2025 63.7 million

INVA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 611.9 million 315.4 million 10.7 million
Dec. 31, 2025 550.9 million 257.7 million 10.9 million
Sept. 30, 2025 533.1 million 313.9 million 1.6 million
June 30, 2025 497.7 million 257.0 million 2.0 million

INVA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 84.8 million
Dec. 31, 2025 85.3 million
Sept. 30, 2025 85.0 million
June 30, 2025 84.5 million

INVA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 492000 5.2 million 32.4 million -
Dec. 31, 2025 1.1 million 4.6 million 32.1 million -
Sept. 30, 2025 1.1 million 13.7 million 27.4 million -
June 30, 2025 - 8.0 million 26.4 million -

INVA Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 98.0 million 22.2 million
Dec. 31, 2025 118.0 million 42.4 million
Sept. 30, 2025 107.8 million 25.8 million
June 30, 2025 100.3 million 10.6 million

INVA Revenue by Segment

Graph available only for paid members. Upgrade to see it.

INVA

Price: $22.42

52 week price:
16.52
25.15

Payout Ratio Range:
-634.79%
30.12%

Earnings Per Share: 6.26 USD

P/E Ratio: 3.60

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 549332

Ebitda: 66.9 million

Market Capitalization: 1.6 billion

Links: